Bone Biologics Co. (OTC:BBLG – Get Free Report)’s stock price was up 2.3% during trading on Thursday . The stock traded as high as $1.7713 and last traded at $1.76. Approximately 34,818 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 45,740 shares. The stock had previously closed at $1.72.
Bone Biologics Stock Performance
The firm has a market capitalization of $3.16 million, a price-to-earnings ratio of -0.49 and a beta of 0.74. The company has a 50-day moving average price of $1.69 and a 200-day moving average price of $2.16.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Featured Articles
- Five stocks we like better than Bone Biologics
- The Crash Has Already Started (Most Just Don’t See It Yet)
- Trump’s AI Secret: 100X Faster Than Nvidia
- Trump Planning to Use Public Law 63-43: Prepare Now
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
